Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers

Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie

doi:10.1007/s40291-013-0070-3

Journal article

Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers

Henry D Reyes, Kristina W Thiel, Matthew J Carlson, Xiangbing Meng, Shujie Yang, Jean-Marie Stephan and Kimberly K Leslie

Molecular diagnosis & therapy, Vol.18(2), pp.137-151

04/2014

DOI: 10.1007/s40291-013-0070-3

PMCID: PMC3969446

PMID: 24403167

Files and links (1)

url

http://doi.org/10.1007/s40291-013-0070-3View

Open Access

Abstract

The primary gynecologic cancers include cancers of the endometrium, ovary, and cervix. Worldwide, cervical cancer is the most common gynecologic cancer, whereas endometrial cancer is the most common in the US. Ovarian cancer is the fifth most deadly cancer in women, with 5-year survival rates for advanced disease at only 27 %. As such, there is an urgent need for reliable screening tools and novel targeted therapeutic regimens for these malignancies. The epidermal growth factor receptor (EGFR)/human EGFR (HER) family of receptors has been associated with the development and progression of many solid tumors. Despite clear roles for these receptors in other cancers, the expression of HER family members in gynecologic cancers and their relationship with disease stage, grade, and response to treatment remain controversial. In this review, we describe the existing evidence for the use of HER family members as diagnostic and prognostic indicators as well as their potential as therapeutic targets in gynecologic cancers.

Genital Neoplasms, Female - diagnosis

Genital Neoplasms, Female - drug therapy

Receptor, Epidermal Growth Factor - metabolism

Prognosis

Humans

Biomarkers, Tumor - metabolism

Receptor, Epidermal Growth Factor - antagonists & inhibitors

Female

Survival Rate

Antineoplastic Agents - therapeutic use

Genital Neoplasms, Female - pathology

Precision Medicine

Details

Title: Subtitle: Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers
Creators: Henry D Reyes - Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, 52242, USA, henry-reyes@uiowa.edu
Kristina W Thiel
Matthew J Carlson - University of Iowa
Xiangbing Meng
Shujie Yang
Jean-Marie Stephan
Kimberly K Leslie
Resource Type: Journal article
Publication Details: Molecular diagnosis & therapy, Vol.18(2), pp.137-151
DOI: 10.1007/s40291-013-0070-3
PMID: 24403167
PMCID: PMC3969446
NLM abbreviation: Mol Diagn Ther
ISSN: 1177-1062
eISSN: 1179-2000
Publisher: New Zealand
Grant note: R01 CA099908 / NCI NIH HHS U10 CA027469 / NCI NIH HHS 5K12HD063117-04 / NICHD NIH HHS CA27469 / NCI NIH HHS K12 HD063117 / NICHD NIH HHS P30 CA086862 / NCI NIH HHS R01CA99908-7 / NCI NIH HHS
Language: English
Date published: 04/2014
Academic Unit: Pathology; Obstetrics and Gynecology
Record Identifier: 9983930415302771

Metrics

27 Record Views

38 Times Cited - Web of Science